FDA calendar: PDUFA dates and approval decisions
Upcoming PDUFA dates disclosed by companies, plus FDA approval decisions, complete response letters and advisory committee meetings. Every entry links to its drug and to the SEC filing or FDA record it came from. Subscribe to the calendar feed (.ics) or get upcoming dates by email each week.
18 matching events. Partial dates are included when their reported period overlaps your range; undisclosed dates have their own view.
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-11-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | GIST | Open original sourceRead source excerptPreparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptWe submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | treatment of hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptThe U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | NonAdvSM | Open original sourceRead source excerptWe submitted the first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026. The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | NonAdvSM | Open original sourceRead source excerptPotential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptWe submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | SCD | Open original sourceRead source excerptWe submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptNew PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-12Day | TinlarebantBelite Bio, Inc · BLTE | Company-disclosed PDUFA goal dateAnnounced review target | Stargardt disease type 1 | Open original sourceRead source excerptU.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027 First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |
| 2027-02-12Day | TinlarebantBelite Bio, Inc · BLTE | Company-disclosed PDUFA goal dateAnnounced review target | Stargardt disease type 1 (STGD1) | Open original sourceRead source excerptNew Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 First seen: 13 Nov 2026 · Evidence last checked: 13 Nov 2026 |
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptan NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptVaregacestat PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027 First seen: 25 Sep 2026 · Evidence last checked: 25 Sep 2026 |
| 2027-05-01Day | AXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSM | Company-disclosed PDUFA goal dateAnnounced review target | cataplexy in narcolepsy | Open original sourceRead source excerptAxsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027. First seen: 02 Nov 2026 · Evidence last checked: 02 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptIn August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | adults with recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptOur NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent LG-IR-NMIBC | Open original sourceRead source excerptIn October 2026, the FDA accepted for review UroGen’s NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027. The NDA is based on clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter trial evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-29Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | AdvSM | Open original sourceRead source excerptPotential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |
Which sources have been checked?
We check SEC filings for company announcements and FDA sources for decisions and notices. Events without a clear match to a company or drug in our database stay unpublished. Scan dates show when checks last ran, not complete coverage.
- Company-disclosed PDUFA dates (SEC)
- Last completed scan: 14 Nov 2026, 17:11 UTC. Latest attempt failed; coverage may be delayed.
- CDER original approvals
- Last completed scan: 18 Nov 2026, 20:10 UTC.
- CDER approval history (Drugs@FDA)
- Last completed scan: 16 Nov 2026, 20:40 UTC.
- CBER original approvals
- Last completed scan: 03 Nov 2026, 21:10 UTC.
- FDA complete response letters
- Last completed scan: 17 Nov 2026, 22:10 UTC.
- FDA advisory committee notices
- Last completed scan: 06 Oct 2026, 23:10 UTC.
If a source gives only a month, quarter or year, we show that rather than an exact day. Learn about our sources
Background: what a PDUFA date is and what a complete response letter is.
Use these dates elsewhere: embed the calendar on your site or read it through the API.
PDUFA dates and the FDA calendar explained
What is a PDUFA date?
A PDUFA date is the target date by which the FDA aims to act on a new drug or biologics application under the Prescription Drug User Fee Act. Standard reviews target about ten months and priority reviews about six. Companies usually disclose the date in a press release or SEC filing once the FDA accepts the application. PDUFA target action date in the glossary
Is a PDUFA date the same as the FDA approval date?
No. The PDUFA date is when the FDA aims to finish its review. On or before that date the agency can approve the application, issue a complete response letter or extend the goal date. This calendar lists PDUFA dates and published FDA decisions as separate event types.
Where do the dates in this FDA calendar come from?
PDUFA dates come from company filings with the US Securities and Exchange Commission. Approval decisions, complete response letters and advisory committee meetings come from FDA publications and Federal Register notices. Every entry links to the source it was taken from.
What happens when a PDUFA date changes?
When a company discloses a revised goal date, the calendar shows the new date and the drug page keeps the earlier date with its source.
How do I add PDUFA dates to my own calendar?
Subscribe to the FDA calendar feed in Google Calendar, Apple Calendar or Outlook using the link on this page. The feed carries upcoming and recent published events reported with an exact day. FDA calendar feed (.ics)